Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors
Johannessen C, Konieczkowski D, Abudayyeh O, Kim J, Cooper Z, Piris A, Frederick D, Barzily-Rokni M, Straussman R, Haq R, Fisher D, Mesirov J, Hahn W, Flaherty K, Wargo J, Tamayo P, Garraway L. Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors. Clinical Cancer Research 2015, 21: pr04-pr04. DOI: 10.1158/1557-3265.pms14-pr04.Peer-Reviewed Original ResearchBRAFV600-mutant melanomaMAPK pathway inhibitorsPathway inhibitorCell linesMelanocyte lineage transcription factor MITFPanel of melanoma cell linesResistance to MAPK pathway inhibitorsMAPK pathway inhibitionReceptor tyrosine kinase AXLDrug-resistant cell linesImprove cancer therapyTyrosine kinase AXLMelanoma cell linesSensitive cell linesNF-kB activationNF-kB signalingRAF/MEK inhibitionMelanoma patientsClinical responseTranscription factor MITFMalignant melanomaDrug susceptibilityAcquired resistancePatient biopsiesMEK inhibitors